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Abstract 
Few medical interventions compete with vaccines for their cumulative impact on health and well-being of entire populations. 
Routine immunization of children in the United States now targets 16 vaccine-preventable diseases; and vaccines are now 
routinely given across the lifespan. Immunization efforts achieved the global eradication of smallpox, as well as the elimination 
of polio, measles, and rubella from the Americas. The childhood vaccine series including DTP, polio, MMR, Hib, hepatitis B, 
and varicella vaccines is estimated to prevent 14 million infections, avoid 33,000 premature deaths, and save $9.9 billion in direct 
medical costs as well as $33 billion in indirect costs for each U.S. birth cohort fully vaccinated. Newer vaccines such as 
pneumococcal conjugate, rotavirus, and hepatitis A vaccines have also reduced illness and hospitalizations among the target 
populations but also have amplified benefits beyond their direct effects through reduced transmission from those immunized to 
other groups. Although for most of the 20th century there was a substantial delay between a vaccine’s introduction in developed 
countries and its broad use in poor countries, newer global public–private partnerships and advocacy are leading to accelerated 
uptake of new and underutilized vaccines. Since the Measles Initiative was established in 2001, more than 700 million children 
worldwide have received a measles vaccination and an estimated 4.3 million childhood measles deaths have been averted. The 
full impact of increasing routine immunization further and implementing new vaccines against pneumonia and diarrhea agents in 
the poorest countries could prevent more than 2 million additional childhood deaths each year. 
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1. Introduction 
Few combinations of scientific development and large-scale delivery rival the impact that vaccines and 
associated immunization programs have had on human health and well being. The scientific and pharmaceutical 
enterprises have developed vaccines to protect humans against dozens of diseases. National immunization programs 
in the United States and beyond have introduced and sustained the delivery of many of these interventions. 
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Immunization programs manage to reach children in nearly every region, neighborhood, and household in the 
population. The cumulative benefits of this collective scientific and public health effort are enormous and include 
extended life expectancy, parental freedom from fears of crippling or life-threatening scourges of childhood, 
disappearance of disruptive community epidemics, and economic savings from averted disease and disability. 
Vaccines protect against several acute infectious diseases and the long-term complications of these infections, which 
range from congenital rubella syndrome to Hepatitis B and Human Papilloma virus related cancers. Much of this 
progress was accomplished over the past 50 years in the developed world, but progress often lagged by decades in 
resource-poor settings. The past decade, however, has seen greatly accelerated impact in developing countries 
through unprecedented levels of public–private partnership and investment. Although numerous challenges continue 
to threaten these successes, the scorecard currently shows science and immunization programs winning the contest 
against the vaccine-preventable diseases they target. 
2. Historical background 
Before the development and wide use of human vaccines, few people survived childhood without experiencing a 
litany of diseases including measles, mumps, rubella, chickenpox, whooping cough, and rotavirus diarrhea. In 
addition to these universal diseases of childhood, thousands of children each year suffered or succumbed to life-
threatening episodes of paralytic poliomyelitis, diphtheria, or bacterial meningitis caused by Haemophilus influenzae 
type b (Hib) or Streptococcus pneumoniae [1]. The extent of annual disease morbidity before and after routine 
vaccine use in the United States is shown in Table 1.  
Table 1. Comparison of pre-vaccine era estimated annual morbidity and current morbidity of selected 
vaccine preventable diseases in the United States 
Disease 20
th Century Annual 
Morbidity [1] 
2009 Reported Cases 
[23] except as specified Percent decrease 
Smallpox 29,005 0 100% 
Diphtheria 21,053 0 100% 
Measles 530,217 71 >99% 
Mumps 162,344 1,991 >99% 
Pertussis 200,752 16,858 92% 
Polio (paralytic) 16,316 1 >99% 
Rubella 47,745 3 >99% 
Congenital rubella syndrome 152 2 99% 
Tetanus 580 18 97% 
Haemophilus influenzae 20,000 213a 99% 
Hepatitis A 117,333 11,049 91% 
Hepatitis B (acute) 66,232 11,269 83% 
Pneumococcus (invasive) 
 <5 years of age 
 
16,069 
 
4,167b 
 
74% 
Varicella 4,085,120 449,363 89% 
a 35 type b and 178 unknown serotype (<5 years of age) 
b Source: www.cdc.gov/abcs/survreports/spneum08.pdf  
The first major grassroots advocacy targeting a disease in the 20th century was championed by Franklin Delano 
Roosevelt and the National Foundation for Infantile Paralysis (a precursor of the March of Dimes) [2]. Polio was 
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familiar to and feared by essentially every parent in America. Through its frequent epidemics and seemingly 
arbitrary attacks on neighbors and classmates, and through the images of life confined to an iron lung, paralytic 
poliomyelitis needed no amplification by Hollywood to capture national concern, which the public channeled into 
contributions (e.g., dimes) and social support for scientific investment in a cure for polio. By 1955, on the tenth 
anniversary of President Roosevelt’s death, investigators announced to a packed auditorium the results of a 
nationwide clinical trial of Salk’s inactivated polio vaccine among schoolchildren, an announcement broadcast live 
across the country [2]. The U.S. immunization program can trace its origins to the major vaccination campaigns that 
followed, first against polio and then against measles and rubella, once vaccines against those diseases were 
developed during the 1960s. Poliomyelitis became rare in the U.S. within years of the initial vaccine campaigns and 
was certified to have been eliminated from the Americas by 1994 [3,4]. 
Perhaps the most extraordinary accomplishment related to vaccines and immunization programs is the global 
eradication of smallpox. This is the first disease of humans to be extinguished from the planet through an 
intentional, organized, and massive undertaking of governments and nongovernmental organizations throughout the 
world [5]. Before the advent of vaccines, some communicable diseases had declined precipitously in developed 
countries through improvements in sanitation, nutrition, housing conditions, and improved indoor air quality. 
However, vaccination can often accelerate disease reduction even in the most impoverished communities before 
such advances are accomplished. The implementation of immunization programs, in fact, may be able to jumpstart 
other prevention and public health efforts. For example, the Expanded Program on Immunization (EPI), introduced 
worldwide in 1974 [6], provided the first basic infrastructure for children’s health services in many poor countries 
and has proved a suitable platform for addressing a variety of health needs.   
3. Progress in vaccines and immunization in the United States  
As recently as 1985, the U.S. immunization system targeted a core of just seven childhood diseases: diphtheria, 
pertussis, tetanus, measles, mumps, rubella, and poliomyelitis. Older adults were recommended to receive annual 
influenza vaccines and pneumococcal polysaccharide vaccines, with decennial tetanus diphtheria boosters 
recommended for all adults. The tools available for prevention have expanded substantially since that time 
(Table 2). Currently, sixteen vaccine-preventable diseases are targeted by pediatric vaccination. All adults are now 
recommended to receive influenza vaccination. A dose of Tdap replaces one decennial tetanus diphtheria booster. 
Since 2006, vaccines against zoster and human papilloma virus are also available. Additional vaccines are 
recommended for people with specific occupational, behavioral, or travel exposures as well as chronic medical 
conditions. 
In the United States, national recommendations for immunization practice are developed by the CDC’s Advisory 
Committee on Immunization Practices (ACIP) and harmonized with health professional organizations including the 
American Academy of Pediatrics and American Academy of Family Physicians [7]. Immunization coverage is 
primarily monitored through the National Immunization Survey (NIS). The NIS estimates of annual progress in 
immunization coverage of toddlers 19 to 35 months of age show that most infant vaccines have achieved 90% 
coverage [8]. The proportion of toddlers who have received no vaccine doses remains less than 1%.  
The NIS also tracks coverage among the nation’s adolescents 13 to 17 years of age [9]. Coverage with a single 
dose of Tdap, meningococcal conjugate, and HPV vaccines continues to rise. However, the proportion of teenage 
girls who had completed the full three-dose HPV series by 2009 was only 26.7%, suggesting need for ongoing 
efforts in this age group.  
Coverage with recommended vaccines among adults continues to lag behind the levels achieved in childhood. 
Multiple factors likely contribute to this gap, including persistent misconceptions that only children need vaccines 
and a greater emphasis on curative over preventive services within the practice of internal medicine.  
4. Health and economic impact of vaccines 
Vaccines save lives and prevent disease and disability, but they also represent good value among health 
interventions. Most of the older vaccines have demonstrated their cost-saving benefits. Newer vaccines are 
systematically reviewed for their cost-effectiveness before routine recommendations are issued by the ACIP [7]. For 
each U.S. birth cohort that receives a series of seven vaccines that protect against 10 different diseases (diphtheria, 
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pertussis, tetanus, measles, mumps, rubella, polio, Hib, hepatitis B, and varicella), an estimated 14 million disease 
episodes and 33,000 premature deaths are prevented [10]. These vaccinations lead to an estimated $43 billion saved,  
including $9.9 billion in direct savings from medical costs and $33 billion saved indirectly through reduction in 
societal costs (e.g., from missed work). The full economic value of some vaccines may only become evident 
following routine use. For example, the cost effectiveness of pneumococcal conjugate vaccines for infants estimated 
prelicensure did not anticipate the substantial herd immunity benefits that vaccinating young children would have on 
disease in adults. An updated analysis found that before accounting for indirect benefits, pneumococcal conjugate 
vaccine cost $201,000 per life year saved; after incorporating indirect benefits on invasive pneumococcal disease, 
costs fell to $10,400 per life year saved [11,12].  
Table 2. Diseases targeted by vaccines recommended for routine use in children in the United States in 1985, 
1995, and 2006 
1985 1995 2006 
Diphtheria 
Pertussis 
Tetanus 
Poliomyelitis 
Measles 
Mumps 
Rubella 
Diphtheria 
Pertussis 
Tetanus 
Poliomyelitis 
Measles 
Mumps 
Rubella 
Haemophilus influenzae type b 
Hepatitis b 
Varicella 
Diphtheria 
Pertussis 
Tetanus 
Poliomyelitis 
Measles 
Mumps 
Rubella 
Haemophilus influenzae type b 
Hepatitis b 
Varicella 
Pneumococcal disease 
Influenza 
Hepatitis A 
Meningococcal disease 
Rotavirus gastroenteritis 
Human papilloma virus 
During the first decade of the 21st century, recommendations for routine use of human vaccines expanded. New 
vaccines licensed during the past decade in the U.S. include pneumococcal conjugate vaccines (first seven valent 
and more recently 13-valent); meningococcal conjugate, tetanus-diphtheria-acellular pertussis booster formulations 
for teens and adults; 2nd generation rotavirus vaccines, human papilloma virus vaccines, and zoster vaccine 
(www.cdc.gov/vaccines/pubs/ACIP-list.htm). Influenza vaccination is now recommended for universal use (i.e., all 
those >6 months of age). Immunization coverage in young children continues to be high enough to sustain the 
elimination of indigenous transmission of measles, rubella, and poliomyelitis, with Hib disease nearing elimination 
among children younger than 5 years of age [8]. Newer vaccines, including pneumococcal conjugate, rotavirus, and 
hepatitis A vaccines, have led to substantial direct and indirect reductions in disease occurrence relatively soon after 
broad use, suggesting that lower thresholds of immunization coverage are needed to yield herd immunity [13-15].   
5. Current challenges in the United States 
Various threats may jeopardize some of the progress in immunization achieved so far in the United States or may 
suggest the need for ongoing investments to sustain a robust system for prevention and response. Challenges include 
concerns related to vaccine safety and vaccine acceptance, vaccine cost and financing, stability and security of 
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vaccine supply, strategies for reaching more adolescents and adults, and improved preparedness for pandemics of 
influenza.  
Public concerns about the safety of vaccines and public complacency regarding the need for vaccine-induced 
protection have been linked to recent outbreaks of vaccine-preventable diseases such as measles [16] and higher 
rates of exemptions from school-entry vaccine requirements [17,18]. During the H1N1 influenza pandemic response 
in 2009-2010, vaccine safety monitoring was a major priority [19,20]. The challenges faced by providers seeking to 
address parents’ concerns related to the immunization schedule, number of injections, and vaccine safety prompted 
an expansion of the efforts in this area by the CDC and the American Academy of Pediatrics, including development 
of a toolkit of materials to address communication needs of health care providers 
(www.cdc.gov/vaccines/conversations). CDC has also expanded the ability to monitor trends in parental concerns in 
conjunction with the ongoing National Immunization Survey.  
Economic factors also challenge the immunization system and public. The cost of vaccines has increased as 
prices set for vaccines licensed since 2000 are substantially higher even for public sector contracts negotiated for the 
Vaccines for Children Program. The Vaccines for Children Program in the United States entitles uninsured, 
American Indian, or Alaskan Native children to receive vaccines without charge. It has greatly narrowed economic, 
racial, and ethnic disparities in immunization coverage among children. The vast majority of insurance plans cover 
ACIP-recommended vaccinations, but pediatricians have expressed concerns regarding the upfront costs they must 
incur in order to stock inventories of higher-priced vaccines and their ability to manage the delay before 
reimbursement is provided [21]. Some providers refer patients to health departments for selected newer vaccines, 
whereas health departments frequently are unable to offer the more expensive of the newer vaccines to underinsured 
or insured patients through their discretionary section 317 vaccine purchase program [22]. The Patient Protection 
and Affordable Care Act of 2010 requires insurance plans to cover ACIP-recommended immunizations with no co-
pays.  
The uptake of recommended vaccines among teens and adults is much lower than that among young children in 
the U.S. [8,9,23]. Infants and toddlers make more frequent medical visits than do adolescents, and preventive or 
well-child visits trail off as children enter their teenage years. Pediatric and adolescent medicine organizations have 
been promoting a preteen health visit, and growth of this practice may address some of the current limits. The HPV 
vaccine offers special challenges, because it requires three doses for full protection. While the initial dose can be 
integrated with meningococcal and Tdap vaccinations, follow-up visits are needed. The limits in health care 
utilization for teens and healthy adults has led to greater interest in nontraditional venues for vaccination, including 
pharmacies and commercial venues, schools, and workplaces. These sites are often more acceptable and convenient 
than doctors’ offices, but systems improvements are needed to assure that alternative venues are linked appropriately 
with immunization registries, adverse event reporting, and insurance reimbursement that can reduce out-of-pocket 
expenses. 
Assuring a stable supply of recommended vaccines is also challenging. There have been multiple vaccine 
shortages in recent years, prompting interim recommendations for reduced dose schedules or prioritized use of 
scarce products (www.cdc.gov/vaccines/vac-gen/shortages/default.htm). As fewer manufacturers currently produce 
most of the recommended vaccines, security of the vaccine supply has become more critical than in earlier decades. 
Another feature that threatens preparedness for vaccine-preventable disease threats is the dependence on older 
technologies for influenza vaccine production. The 2009-H1N1 influenza pandemic response relied on egg-based 
vaccine production and, although large amounts of monovalent H1N1 influenza A vaccines were eventually 
produced, the majority of doses were not available for use until after the Fall wave of disease in the United States 
had peaked [24,25]. Investments in incremental improvements of current procedures, including improved methods 
for potency testing and identification of candidate reassortant vaccine strains, may reduce production time by several 
weeks. Even greater improvements may be possible with newer molecular approaches to vaccine production that do 
not rely on growth of the virus. 
6. International trends and opportunities 
The benefits of human vaccines in the United States are dwarfed by the international health impact that can be 
achieved for vaccines used in resource-poor areas where mortality and morbidity from vaccine-preventable diseases 
are higher. International immunization partnerships and initiatives are tackling global polio eradication, measles 
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mortality reduction, and elimination of epidemic meningitis in Africa, among other targets. New and underutilized 
vaccines against the leading childhood killers, pneumonia and diarrhea, are more frequently available through the 
GAVI Alliance (formerly the Global Alliance for Vaccines and Immunization) and investments from organizations 
such as the Bill and Melinda Gates Foundation, which are catalyzing advances in development of vaccines against 
other major killers such as malaria and tuberculosis [27]. The U.S. Government’s commitment through the Global 
Health Initiative and broad engagement in targeting the Millennium Development Goal to reduce child mortality 
also suggest a bright future for expanded use of vaccines for people around the world 
(http://www.usaid.gov/our_work/global_health/home/Publications/docs/ghi_consultation_document.pdf and 
http://www.un.org/millenniumgoals/). 
7. Conclusion 
While much has been achieved through use of human vaccines, the potential for further impact is substantial. 
Scientific advances can be applied to hasten production and simplify delivery of vaccines, but social and political 
commitment to immunization programs must be sustained to reap the full benefits of these tremendous medical 
discoveries. 
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